MedWatch

Specialists: Eli Lilly has good data, but Novo's Ozempic has the lead

Data are promising for US drug group Eli Lilly's new diabetes therapy, according to two Danish obesity- and diabetes specialists. However, they stress that Novo Nordisk's Ozempic maintains the edge over Eli Lilly. Data about side-effects and cardiovascular diseases can be pivotal to the drugs' success.

Photo: Vincent Kessler/Ritzau Scanpix

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles